Beam Brings In $135M to Turn CRISPR Base Editing into Drugs
Beam Therapeutics made a splash last year when it launched with $87 million to develop medicines that use a more precise form of CRISPR...
Beam Brings In $135M to Turn CRISPR Base Editing into Drugs
Gossamer Bio pulls off $276M IPO to push a trio of programs through the clinic
Indigo Agriculture Launches Indigo Transport™, a Digital Logistics Platform to Expand Options for Gr
BlackThorn Therapeutics Announces R&D Updates
Indigo Ag, Inc. Acquires TellusLabs, a Leader in Satellite Technology and Artificial Intelligence, t
Millendo Therapeutics Announces Successful Merger Completion
Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
eFFECTOR Therapeutics Announces Clinical Collaboration with Merck to Conduct a Phase 2 Combination T
FierceBiotech names Gossamer Bio as one of its “Fierce 15” biotech companies of 2018